Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of SYNT001 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1a, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of SYNT001 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 17 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orilanolimab (Primary)
  • Indications Autoimmune disorders; Pemphigus
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Syntimmune

Most Recent Events

  • 12 Dec 2017 Status changed from recruiting to completed as the tIgG stopping rule was reached, according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
  • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
  • 01 Nov 2017 Results presented in an Syntimmune media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top